Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock surges as Mysimba gets European approval Print E-mail
By Marilyn Mullen   
Friday, 27 March 2015 13:49

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has confirmed that its weight-loss drug Mysimba  has been approved by European Commission which can be used with a low-calorie diet as well as increased physical activity for patients who want lose weight. This resulted in Orexigen stocks to surge by 8.8% in the extended trading session yesterday.

The European Commission has specified that the medicine should be only used for overweight and obese people with a starting Body Mass Index (BMI) of 27 kg/m2. This drug can also be used by adults having one or more weight-related co-morbidities like type II diabetes or controlled hypertension. The approval for the medicine is for all the 28 European Union member states. Obesity is a huge public health issue world over and obese people have high incidence rate of chronic diseases like diabetes and cardiovascular problems.

As per the World Health Organization, over 20% European adults are obese and the number has only surged over the last two decades.

About 6% healthcare costs in Europe are connected to obese individuals. The disorder leads to indirect expenses like loss of productivity and income and the costs of these are estimated to over twice that of direct costs.

An anti-obesity pill, Mysimba comprises of antagonist called Naltrexone as well as a norepinephrine and dopamine reuptake inhibitor called bupropion.

The drug’s active substances work by impacting various areas of the brain for influencing eating behavior in the patients.

The efficacy of the drug along with controlled diet as well as exercise, was done in several final-stage clinical trials conducted on 4,536 obese patients. The results showed that clinically-relevant weight loss as compared to a placebo pill.

The adverse effects from drug usage involved nausea, dizziness, vomiting, constipation, insomnia, dry mouth, as well as diarrhea.

Mysimba got the US Food and Drug Administration’s approval in the previous year.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter